Qiagen N.V. (NASDAQ: QGEN) and Celyad SA (NASDAQ:CYAD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.

Volatility & Risk

Qiagen N.V. has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, Celyad SA has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500.

Profitability

This table compares Qiagen N.V. and Celyad SA’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Qiagen N.V. 5.44% 11.04% 6.53%
Celyad SA N/A N/A N/A

Institutional & Insider Ownership

63.0% of Qiagen N.V. shares are owned by institutional investors. Comparatively, 4.1% of Celyad SA shares are owned by institutional investors. 9.0% of Qiagen N.V. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Qiagen N.V. and Celyad SA’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Qiagen N.V. $1.36 billion 5.94 $443.36 million $0.33 108.70
Celyad SA $13.77 million 41.52 -$23.29 million N/A N/A

Qiagen N.V. has higher revenue and earnings than Celyad SA.

Analyst Ratings

This is a summary of recent recommendations and price targets for Qiagen N.V. and Celyad SA, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qiagen N.V. 0 7 5 0 2.42
Celyad SA 0 0 1 0 3.00

Qiagen N.V. presently has a consensus price target of $32.56, indicating a potential downside of 7.94%. Celyad SA has a consensus price target of $74.00, indicating a potential upside of 23.29%. Given Celyad SA’s stronger consensus rating and higher possible upside, analysts plainly believe Celyad SA is more favorable than Qiagen N.V..

Summary

Qiagen N.V. beats Celyad SA on 8 of the 12 factors compared between the two stocks.

About Qiagen N.V.

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company’s automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

About Celyad SA

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.